5 Stocks Pushing The Health Services Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 39 points (-0.3%) at 13,960 as of Monday, Feb. 25, 2013, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,475 issues advancing vs. 1,392 declining with 148 unchanged.

The Health Services industry currently sits down 0.1% versus the S&P 500, which is down 0.1%. Top gainers within the industry include Opko Health ( OPK), up 4.0%, Mindray Medical International ( MR), up 1.9%, Cooper Companies ( COO), up 1.6%, Agilent Technologies ( A), up 0.6% and Baxter International ( BAX), up 0.6%. On the negative front, top decliners within the industry include Smith & Nephew ( SNN), down 1.2%, and Intuitive Surgical ( ISRG), down 0.4%.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:

5. Quest Diagnostics ( DGX) is one of the companies pushing the Health Services industry higher today. As of noon trading, Quest Diagnostics is up $0.41 (0.7%) to $56.16 on heavy volume Thus far, 1.1 million shares of Quest Diagnostics exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $55.99-$56.60 after having opened the day at $56.16 as compared to the previous trading day's close of $55.75.

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. Quest Diagnostics has a market cap of $8.9 billion and is part of the health care sector. The company has a P/E ratio of 11.4, below the S&P 500 P/E ratio of 17.7. Shares are down 3.7% year to date as of the close of trading on Friday. Currently there is 1 analyst that rates Quest Diagnostics a buy, 2 analysts rate it a sell, and 14 rate it a hold.

TheStreet Ratings rates Quest Diagnostics as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Quest Diagnostics Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you liked this article you might like

Cramer: These Sectors Look Bullish (Part III)

Cramer: There Are Powerful Themes in Several Bull Markets

Stanley Black & Decker, Quest Diagnostics and 2 More Could Rocket Higher This Spring -- Here's Why

MasterCard, Intuitive Surgical and 2 More Could Rocket Higher This Spring--Here's Why …

Market Recon: If You Are Scared, Don't Show It